DataMeds AI terminates second amended and restated letter of intent
DataMeds AI terminated the second amended and restated letter of intent dated October 19, 2026 for an in-license or acquisition of intellectual property in exchange for DataMeds AI common stock, citing market conditions. The company said no shares will be issued in connection with the terminated LOI and that it owes no fees or obligations as a result of the termination. Its exclusive license with REBOOT and its PharmacyChain agreement with Datavault AI remain in force.
Key takeaways
The terminated LOI was dated October 19, 2026.
The contemplated transaction involved an in-license or acquisition of intellectual property in exchange for DataMeds AI common stock.
DataMeds AI attributed the termination to market conditions.
No shares will be issued in connection with the terminated LOI.
DataMeds AI stated that it owes no fees or obligations resulting from the termination.
The exclusive license with REBOOT for management of GLP-1 users remains in force.
The Datavault AI agreement for PharmacyChain manufacturer-to-patient blockchain-enabled smart contracts remains in force, and no shares were issued to Datavault under that agreement.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.